VLValerie S. LeBleu

Valerie S. LeBleu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valerie S. LeBleu has a total of 261 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pancreatic ductal adenocarcinoma: The Vision of Heracles

    by Carmen Mota Reyes, Mara R Goetz, Hana Algül, Alper Dogruoez, Chiara Falcomatà, Matthias M Gaida, Kıvanç Görgülü, Yetiş Gültekin, Ibrahim Halil Gürcinar, Marie C Hasselluhn, et al.

  • Open Access

    TGF-β2-induced Snail-mediated EndMT signaling relies on both Smad-dependent and independent pathways

    by Valerie S. Kalluri, Bingrui Li, Anais M. Comptdaer, Michelle Kirtley, Kent A. Arian, Xunian Zhou, Raghu Kalluri

    Endothelial-to-mesenchymal transition (EndMT) has become a central mechanism in developmental biology, fibrosis, vascular disease, and cancer. We previously reported on an integrated signaling model in which TGF-β2 induces EndMT through coordinated activation of Smad-dependent and Smad-independent signaling pathways converging on Snail, while GSK-3β regulates Snail activity. We performed a systematic figure-by-figure reproducibility analysis of the original publication. Independent studies published between 2011 and 2026 were identified and curated according to predefined inclusion criteria. Each original experimental conclusion was evaluated for independent confirmation. In parallel, selected biochemical experiments were independently reproduced using newly acquired reagents and contemporary Western blot methodologies. Independent publications consistently reproduced each major mechanistic conclusion of the original study, including activation of Smad, ERK, PI3K/AKT, and p38 MAPK signaling, regulation of Snail expression, EndMT-associated marker switching, and GSK-3β-dependent control of Snail activity. Independent laboratory experiments reproduced the principal biochemical findings using contemporary reagents and experimental workflows. The combined literature analysis and independent laboratory replication demonstrate that the mechanistic framework in our previous study has remained reproducible across multiple laboratories, endothelial cell types, disease models, and fifteen years of investigation. This work illustrates a complementary framework for assessing reproducibility that integrates direct experimental replication with cumulative independent validation.

  • Open Access

    Differential Akt Signaling Induced by Tumstatin and Endostatin in Human Endothelial Cells

    by Valerie S. Kalluri, Raghu Kalluri

    Tumstatin and Endostatin are endogenous extracellular matrix-derived inhibitors of angiogenesis generated from the non-collagenous domains of type IV and type XVIII collagens, respectively. Although both molecules suppress angiogenesis and tumor growth in vivo, previous studies demonstrated that they engage distinct endothelial integrin receptors and activate different intracellular signaling pathways. In particular, Tumstatin inhibits endothelial proliferation through suppression of the focal adhesion kinase (FAK)/phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway, whereas Endostatin primarily inhibits endothelial migration through α5β1 integrin-dependent signaling. Here we evaluated a key mechanistic distinction between these two angiogenesis inhibitors by examining Akt phosphorylation in human umbilical vein endothelial cells (HUVEC) cultured on fibronectin. Validating previous reports, recombinant human Tumstatin reduced Akt phosphorylation whereas recombinant human Endostatin did not alter Akt activation. These findings confirm a defining feature of Tumstatin signaling and reinforce the concept that collagen-derived angiogenesis inhibitors regulate endothelial cell behavior through distinct integrin-dependent mechanisms.

  • Open Access

    Advancements in extracellular vesicle research

    by Bingrui Li, Valerie S. Kalluri, Alissa M. Weaver, Irene Bertolini, John J.S. Cadwell, Ameya Chaudhari, Saumya Das, Zankruti Dave, Jose Francis-Oliveira, Samir El Andaloussi, et al.


  • Open Access

    Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial

    by Valerie S. Kalluri, Bruno Bockorny, Evelio Perea Borobio, Teresa Macarulla, Roberto Pazo Cid, Laura Medina, Aitziber Gil-Negrete, Fernando Rivera, Vanesa Varela, Alejandro Martin-Munoz, et al.

    Metastatic pancreatic ductal adenocarcinoma (PDAC) remains deadly, with minimal improvement in prognosis over the past 20 years despite expansion of our chemotherapeutic arsenal. The complex tumor microenvironment (TME) of PDAC in the advanced stage, which often accompany clinical diagnosis, likely contributes to the limited efficacy of current standard of care chemotherapy. Informed by mechanistic preclinical studies, we evaluated the impact of inhibition of Hedgehog (Hh) signaling to prime PDAC TME and leverage anti-tumor efficacy of Gemcitabine plus nab-Paclitaxel (GnP) together with anti-CTLA-4 immune check point inhibitor (ICI, zalifrelimab). Hh inhibition using NLM-001 (an oral small molecule inhibitor of Smo) aimed to polarize the PDAC TME, including cancer associated fibroblasts (CAFs) and intratumoral immune profile, and to foster an immunosuppressive milieu that engages ICI. In this Phase 1b/2, open label, single arm study, patients with metastatic PDAC received standard GnP every 28-day cycles. In addition, NLM-001 was given at 800 mg daily on days -4 to -1 and days 10 to 13 of the GnP cycles 1 to 3, 6 to 8, 11 to 13 onwards (3 cycles on, followed by 2 rest cycles). Anti CTLA-4 inhibitor, zalifrelimab, was administered at 1mg/kg on day 15 of cycle 1 and every 6 weeks thereafter. The primary end point was to assess efficacy by objective response rate (ORR) as per RECIST v1.1. Treatment was overall well tolerated in the 28 patients enrolled. Most frequent grade 3-4 adverse events (AEs) were neutropenia (46.4%), asthenia (21.4%), and neurotoxicity (14.3%). No patient discontinued treatment due to toxicity. ORR was 50% [95% CI, 29.1-70.9] and disease control rate was 95.5% [95% CI, 86.8 - 100.0]. Median progression-free survival (PFS) was 7.3 months 95.5% [95% CI, 5.564 – 9.041] and median overall survival (OS) was 11.5 months [95% CI, 10.23 –12.73]; 1-year PFS was 18.2% [95% CI, 2.1 – 34.3] and 1-year OS was 50% [95% CI, 29.0 – 710]. Patients who achieved ctDNA clearance at cycle 4 had a significant better PFS (10.7 vs 6.0 months; p+ and CD8 + T cells infiltration, down trending Tregs, and decreased αSMA/FAP ratio. Hedgehog inhibitor NLM-001 in combination with gemcitabine/nab-paclitaxel and zalifrelimab was safe and well tolerated and showed encouraging objective responses in the first line treatment of advanced PDAC. Clinical Trial Registration: EudraCT: 2020-004932-52; NCT04827953 .

  • Top Cited Papers
    Open Access

    Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates

    by Valerie S. Kalluri, Brandon G. Smaglo, Krishnan K. Mahadevan, Michelle L. Kirtley, Kathleen M. McAndrews, Mayela Mendt, Sujuan Yang, Ana S. Maldonado, Hikaru Sugimoto, Maria E. Salvatierra, et al.

    Oncogenic KRAS is amongst the key genetic drivers for initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal a biodistribution in pancreas with negligible toxicity in preclinical studies in mice and Rhesus macaques. Clinical testing of iExoKrasG12D in the iEXPLORE (iExoKrasG12D in Pancreatic Cancer) Phase I study employed a non-randomized single-arm classical 3 + 3 dose escalation design (Phase Ia), followed by an accelerated titration design (Phase Ib) (NCT03608631). The primary outcomes included safety, tolerability and target engagement, and the secondary outcomes aimed to assess disease control. Patients with advanced metastatic disease were enrolled after failure of multiple lines of therapy. iExoKrasG12D therapy was well-tolerated: the primary outcomes were met with iExoKrasG12D showing no dose-limiting toxicity. The maximum tolerated dose was not reached even at the highest dose. In some cases, iExoKrasG12D therapy was associated with stable disease response (secondary outcome). Downregulation of KRASG12D DNA and suppression of phospho-Erk was documented together with an increase in intratumoral CD8+ T cells following treatment. The CD8+ T cell recruitment priming by iExoKrasG12D informed on potential efficacy of immune checkpoint therapy and lead to validation testing in preclinical PDAC models. Combination therapy of iExoKrasG12D and anti-CTLA-4 antibodies, but not anti-PD1, revealed robust pre-clinical anti-tumor efficacy via FAS mediated CD8+ T cell anti-tumor activity. This first-in-human, precision medicine clinical trial and supporting preclinical functional studies offer new insights into priming of immunotherapy by oncogenic Kras inhibitor for future opportunistic combination therapy for PDAC patients.


  • Open Access

    KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients

    by Valerie S. LeBleu, Brandon G. Smaglo, Krishnan K. Mahadevan, Michelle L. Kirtley, Kathleen M. McAndrews, Mayela Mendt, Sujuan Yang, Ana S. Maldonado, Hikaru Sugimoto, Maria E. Salvatierra, et al.

    Oncogenic KRAS drives initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with Kras G12D specific siRNA (iExoKras G12D ) reveal impressive biodistribution in pancreas with negligible toxicity in preclinical studies in mice and Rhesus macaques. Clinical testing of iExoKras G12D in the iEXPLORE (iExoKras G12D in Pancreatic Cancer) Phase I study employed a classical 3+3 dose escalation design (Phase Ia), followed by an accelerated titration design (Phase Ib) ( NCT03608631 ). Patients with advanced metastatic disease were enrolled after failure of multiple lines of therapy. iExoKras G12D therapy was well-tolerated with no reported dose-limiting toxicity with some cases of stable disease response, and maximum tolerated infusion was not reached even at the highest dose. Downregulation of KRAS G12D DNA and suppression of phopho-Erk was documented with increased intratumoral in CD8 + T cell infiltration in patient samples upon treatment. The CD8 + T cell recruitment priming by iExoKras G12D informed on potential efficacy of immune checkpoint therapy and lead to validation testing in preclinical PDAC models. Combination therapy of iExoKras G12D and anti-CTLA-4 antibodies, but not anti-PD1, revealed robust anti-tumor efficacy via FAS mediated CD8 + T cell anti-tumor activity. This first-in-human, precision medicine clinical trial offers new insights into priming of immunotherapy by oncogenic Kras inhibitor and an opportunistic combination therapy for PDAC patients.


  • Open Access

    Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome

    by Valerie S LeBleu, Keizo Kanasaki, Sara Lovisa, Joseph L Alge, Jiha Kim, Yang Chen, Yingqi Teng, Behzad Gerami-Naini, Hikaru Sugimoto, Noritoshi Kato, et al.

    Glomerular filtration relies on the type IV collagen (ColIV) network of the glomerular basement membrane, namely, in the triple helical molecules containing the α3, α4, and α5 chains of ColIV. Loss of function mutations in the genes encoding these chains (Col4a3,Col4a4, andCol4a5) is associated with the loss of renal function observed in Alport syndrome (AS). Precise understanding of the cellular basis for the patho-mechanism remains unknown and a specific therapy for this disease does not currently exist. Here, we generated a novel allele for the conditional deletion ofCol4a3in different glomerular cell types in mice. We found that podocytes specifically generate α3 chains in the developing glomerular basement membrane, and that its absence is sufficient to impair glomerular filtration as seen in AS. Next, we show that horizontal gene transfer, enhanced by TGFβ1 and using allogenic bone marrow–derived mesenchymal stem cells and induced pluripotent stem cells, rescuesCol4a3expression and revive kidney function in Col4a3-deficient AS mice. Our proof-of-concept study supports that horizontal gene transfer such as cell fusion enables cell-based therapy in Alport syndrome.


  • Open Access

    Identification of unique α4 chain structure and conserved antiangiogenic activity of α3NC1 type IV collagen in zebrafish

    by Valerie S. LeBleu, Jianli Dai, Susan Tsutakawa, Brian A. MacDonald, Joseph L. Alge, Malin Sund, Liang Xie, Hikaru Sugimoto, John Tainer, Leonard I. Zon, et al.

    Background: Type IV collagen is an abundant component of basement membranes in all multicellular species and is essential for the extracellular scaffold supporting tissue architecture and function. Lower organisms typically have two type IV collagen genes, encoding α1 and α2 chains, in contrast with the six genes in humans, encoding α1–α6 chains. The α chains assemble into trimeric protomers, the building blocks of the type IV collagen network. The detailed evolutionary conservation of type IV collagen network remains to be studied.Results: We report on the molecular evolution of type IV collagen genes. The zebrafish α4 non‐collagenous (NC1) domain, in contrast with its human ortholog, contains an additional cysteine residue and lacks the M93 and K211 residues involved in sulfilimine bond formation between adjacent protomers. This may alter α4 chain interactions with other α chains, as supported by temporal and anatomic expression patterns of collagen IV chains during the zebrafish development. Despite the divergence between zebrafish and human α3 NC1 domain (endogenous angiogenesis inhibitor, Tumstatin), the zebrafish α3 NC1 domain exhibits conserved antiangiogenic activity in human endothelial cells.Conclusions: Our work supports type IV collagen is largely conserved between zebrafish and humans, with a possible difference involving the α4 chain.


  • Open Access

    Oncogenic Kras G12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 + T cells dependent manner

    by Krishnan K. Mahadevan, Kathleen M. McAndrews, Valerie S. LeBleu, Sujuan Yang, Hengyu Lyu, Bingrui Li, Amari M. Sockwell, Michelle L. Kirtley, Sami J. Morse, Barbara A. Moreno Diaz, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is associated with mutations in Kras, a known oncogenic driver of PDAC; and the KRAS G12D mutation is present in nearly half of PDAC patients. Recently, a non-covalent small molecule inhibitor (MRTX1133) was identified with specificity to the Kras G12D mutant protein. Here we explore the impact of Kras G12D inhibition by MRTX1133 on advanced PDAC and its influence on the tumor microenvironment. Employing different orthotopic xenograft and syngeneic tumor models, eight different PDXs, and two different autochthonous genetic models, we demonstrate that MRTX1133 reverses early PDAC growth, increases intratumoral CD8 + effector T cells, decreases myeloid infiltration, and reprograms cancer associated fibroblasts. Autochthonous genetic mouse models treated with MRTX1133 leads to regression of both established PanINs and advanced PDAC. Regression of advanced PDAC requires CD8 + T cells and immune checkpoint blockade therapy (iCBT) synergizes with MRTX1133 to eradicate PDAC and prolong overall survival. Mechanistically, inhibition of mutant Kras in advanced PDAC and human patient derived organoids (PDOs) induces Fas expression in cancer cells and facilitates CD8 + T cell mediated death. These results demonstrate the efficacy of MRTX1133 in different mouse models of PDAC associated with reprogramming of stromal fibroblasts and a dependency on CD8 + T cell mediated tumor clearance. Collectively, this study provides a rationale for a synergistic combination of MRTX1133 with iCBT in clinical trials.